Medicare AdvantageCoverageMedium impact
MA08.090h, Lanreotide (Somatuline® Depot)
Independence Blue Cross·Endocrinology, Oncology, Gastroenterology·Pharmacy
Effective date
Nov 17, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated the medical necessity criteria and medical coding requirements for Lanreotide (Somatuline Depot) injections. This affects billing and coverage determination for this specialty medication used to treat certain endocrine disorders.
Action Required
By November 17, 2025: Billing team must review updated medical necessity criteria for Lanreotide (Somatuline Depot) claims. Update prior authorization documentation requirements and verify medical coding guidelines are current in billing system. Providers should ensure documentation meets new medical necessity standards to prevent claim denials.